Similar articles for PMID: 20386540

Year	Number of Results
1998	1
1999	2
2000	1
2001	3
2002	2
2003	2
2004	4
2005	6
2006	6
2007	9
2008	6
2009	7
2010	7
2011	10
2012	8
2013	7
2014	9
2015	6
2016	6
2017	6
2018	5
2019	4
2020	6
2021	6
2022	11
2023	6
2024	0

1

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA. Evans AH, et al. Br J Cancer. 2010 Apr 13;102(8):1235-43. doi: 10.1038/sj.bjc.6605641. Br J Cancer. 2010. PMID: 20386540 Free PMC article.

2

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M. Martin LA, et al. Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330. Breast Cancer Res. 2012. PMID: 23075476 Free PMC article.

3

Aromatase inhibitors and xenograft studies.

Chumsri S, Sabnis GJ, Howes T, Brodie AM. Chumsri S, et al. Steroids. 2011 Jul;76(8):730-5. doi: 10.1016/j.steroids.2011.02.033. Epub 2011 Mar 21. Steroids. 2011. PMID: 21420993 Free PMC article.

4

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A. Andreucci E, et al. Oncotarget. 2016 Dec 6;7(49):80543-80553. doi: 10.18632/oncotarget.11826. Oncotarget. 2016. PMID: 27602955 Free PMC article.

5

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.

Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. Marcom PK, et al. Breast Cancer Res Treat. 2007 Mar;102(1):43-9. doi: 10.1007/s10549-006-9307-8. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897431 Clinical Trial.

6

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D. Brodie A, et al. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102. doi: 10.1016/j.jsbmb.2006.09.002. J Steroid Biochem Mol Biol. 2006. PMID: 17113978 Free PMC article.

7

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Long BJ, et al. J Natl Cancer Inst. 2004 Mar 17;96(6):456-65. doi: 10.1093/jnci/djh076. J Natl Cancer Inst. 2004. PMID: 15026471

8

Letrozole in the neoadjuvant setting: the P024 trial.

Ellis MJ, Ma C. Ellis MJ, et al. Breast Cancer Res Treat. 2007;105 Suppl 1(Suppl 1):33-43. doi: 10.1007/s10549-007-9701-x. Epub 2007 Oct 3. Breast Cancer Res Treat. 2007. PMID: 17912634 Free PMC article. Clinical Trial.

9

Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.

Kijima I, Itoh T, Chen S. Kijima I, et al. J Steroid Biochem Mol Biol. 2005 Dec;97(4):360-8. doi: 10.1016/j.jsbmb.2005.09.003. Epub 2005 Nov 2. J Steroid Biochem Mol Biol. 2005. PMID: 16263272

10

Co-targeting estrogen receptor and HER2 pathways in breast cancer.

Mehta A, Tripathy D. Mehta A, et al. Breast. 2014 Feb;23(1):2-9. doi: 10.1016/j.breast.2013.09.006. Epub 2013 Oct 28. Breast. 2014. PMID: 24176518 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

128 results

Results by year